

Early and Locally Advanced Breast Cancer (update)

Committee meeting 3

Date: 19/12/16

Location: RCOG, London

Minutes: Confirmed

Committee members present:	
Jane Barrett	(Present for notes 1 – 8)
Anne Armstrong	(Present for notes 1 – 8)
Carmel Gulliver-Clarke	(Present for notes 1 – 8)
Ramsey Cutress	(Present for notes 1 – 8)
Linda Pepper	(Present for notes 1 – 8)
Mia Rosenblatt	(Present for notes 1 – 8)
Lisa Whisker	(Present for notes 1 – 8)
Sairanne Wickers	(Present for notes 1 – 8)
Roger Hunt	(Present for notes 1 – 8)
Ursula Van Mann	(Present for notes 1 – 8)
William Teh	(Present for notes 1 – 8)
Peter Jenkins	(Present for notes 1 – 8)
Faye Coe	(Present for notes 1 – 8)

In attendance:		
Clifford Middleton	NICE Guideline Commissioning Manager	(Present for notes 1 – 6)
John Graham	NGA Clinical Adviser	(Present for notes 1 – 8)
Angela Bennett	NGA Guideline Lead	(Present for notes 1 – 8)
Matthew Prettyjohns	NGA Senior Health Economist	(Present for notes 1 – 8)
Nathan Bromham	NGA Senior Systematic Reviewer	(Present for notes 1 – 8)
Laura O’Shea	NGA Systematic Reviewer	(Present for notes 1 – 8)
Lianne Gwillim	NGA Project Manger	(Present for notes 1 – 8)

Observers:	
None	

Apologies:		
Sadaf Haque	Committee member	(Absent for notes 1-8)
Marina Parton	Committee member	(Absent for notes 1-8)
Imogen Locke	Committee member	(Absent for notes 1-8)
Ferruccio Pelone	NGA Assistant Systematic Reviewer	(Absent for notes 1-8)

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 3rd meeting on Early and Locally Advanced Breast Cancer (update).

No members of the public asked to observe the meeting.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting which included: agreeing PICOs for remaining questions, signing off existing review protocols, agreeing which questions are priorities for health economic analysis

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Early and locally advanced breast cancer.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Ramsey Cutress	Consultant Surgeon and Associate Professor, Southampton General Hospital	Undertakes private medical practice. Services provided are identical to that of NHS practice [November 2016]	Personal financial, specific	Declare and participate in discussions on all topics as private practice is aligned with standard NHS care
Ramsey Cutress	Consultant Surgeon and Associate Professor, Southampton	Have previously reviewed a patient information leaflet for Breast	Personal non-financial, specific	Declare and participate

	General Hospital	Cancer Care, and review the Cancer Research UK webpages [November 2016]		
Ramsey Cutress	Consultant Surgeon and Associate Professor, Southampton General Hospital	Co-investigator on an application for NIHR portfolio adoption for CAND02 [November 2016]	Non-personal financial, non-specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
Ramsey Cutress	Consultant Surgeon and Associate Professor, Southampton General Hospital	Has been asked to organise department annual scientific conference for 2017. As part of this will need to write to ask for sponsorship from several companies to offset the costs of the conference. They will have stands at the meeting to promote their laboratory research products but no input into the content of the conference. The funds will go into a unit account that I will not be signatory to. [November 2016]	Non-personal financial specific	Declare and participate as funds to into a unit account that is not a signatory for. Also companies have no input into content of conference.
Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer,	Have reviewed a pregnancy and cancer leaflet for Macmillan	Personal, non-financial, nonspecific	Declare and participate

	The Christie NHS Foundation Trust	[November 2016]		
Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	Local PI for Keynote 173 – looking at use of pre-op pembrolizumab in people with early breast cancer. Trial funded by Merck. No involvement in designing trial protocol	Non-personal financial, non-specific	Declare and participate as pembrolizumab is not being investigated by the guideline and no supervisory responsibility for the trail
Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	Local PI for Neo-21- neoadjuvant phase II trial for ER+ early breast cancer patients. Using oncotype to identify patients with an intermediate recurrence score – these patients will be randomised to letrozole +/- palbociclib. Have given oncology input to the protocol. Funded by University of Liverpool and Clatterbridge	Non-personal financial, non-specific	Declare and participate as no supervisory responsibility for the trial
Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	Local PI for Aurora (biopsies are being gene analysed to look for potentially (drug)-targetable mutations/ pathway activations) in metastatic breast cancer. Funded by Breast	Non-personal financial non-specific	Declare and participate as guideline is not covering metastatic breast cancer.

		International Group. No involvement in designing trial protocol		
Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	Local PI for Optima. Using Prosignia (another oncotype-dx type test) to determine whether chemotherapy is needed or not in ER+ node+ early breast cancer. No input into protocol. Sponsored by NHS- UCL	Non-personal financial non-specific	Declare and participate as no supervisory responsibility for trial and oncotype-dx is not being investigated by this guideline.

The Chair and a senior member of the Developer’s team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Minutes of last meeting

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

4. Presentations

The Chair introduced Nathan Bromham, who gave a presentation on Minimally important difference (MID). Nathan took questions from the group.

The Chair introduced Matthew Prettyjohns, who gave a presentation on the health economic priorities for investigation in the guideline. The Committee then discussed the issues presented in relation to this guideline.

5. Questions and discussion

The Committee discussed the draft review questions for 3.2, 6.1, 9.2, 10.1, 10.3 & 10.4 and agreed the revised question, PICO, Health Economic priority, and sub-

group members for these questions.

The committee discussed the review protocols for questions 1.1, 2.1, 2.2, 4.1, 5.1, 7.1, 8.1, 8.3, 8.4, 9.1 and 10.2, made amendments where needed and signed off these review protocols.

6. Any other business

No service user or carer concerns were raised.

Date of next meeting: 19th January 2017

Location of next meeting: RCOG, London